News

Development and characterization of narsoplimab a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders

Written by Svar Life Science | Mar 4, 2024 7:30:00 AM

NEW Complement solutions  CITATION

In this recent study, the Wieslab® Complement System Screen ELISA kit was used to determine the specificity of a novel monoclonal antibody that targets the Lectin Pathway.